- >=99.0 HPLCHPLC / MSIn stock
Research compound
FOXO4
FOXO4-DRI is an all-D-amino acid retro-inverso peptidomimetic engineered to replicate the FOXO4 domain responsible for p53 retention within senescent cells. Its mechanism of action is competitive occupancy of the FOXO4-p53 binding interface, releasing p53 and enabling apoptotic signaling with documented selectivity for p21-high senescent cell populations in culture models. The compound defines the pharmacological template for p53-releasing senolytic research and is the primary reference tool for mechanistic cellular senescence pathway characterization. Supplied lyophilized for in vitro research use only.
Specification
- CAS
- 2460055-10-9
- Molecular weight
- 5358.06 g/mol
- Formula
- C228H388N86O64
- Purity
- >=99.0 HPLC
- Storage
- -20 °C, lyophilized
Size
Research notes
What is FOXO4?
FOXO4 is a synthetic research compound studied in laboratory settings. It has molecular formula C228H388N86O64, a molecular weight of 5358.06 g/mol, CAS 2460055-10-9. It is intended for in vitro research use only and is not for human or animal use.
What purity is Valitec Peptides's FOXO4?
Valitec Peptides supplies FOXO4 at >=99.0% purity, verified by third-party HPLC analysis. A certificate of analysis is available on request.
How is FOXO4 supplied?
FOXO4 is supplied as a lyophilized powder in sealed research-grade vials, stored -20 °C, lyophilized, intended for in vitro and laboratory research use only.
For laboratory research use only. Not for human or veterinary use, and not for diagnostic or therapeutic use.